While testosterone is responsible for male characteristics like muscle mass and body hair, oestrogen regulates fat distribution and the growth of breast tissue. In hypogonadal patients, treatment with T may lead to regression by producing androgens, although in some patients T may get aromatized to E2, resulting in further breast enlargement.2,11 Dialysis or re-feeding related gynecomastia is usually self-limited and reassurance may be sufficient. Local tissue factors in the breast can also be important; for example, increased aromatase activity that can cause excessive local production of estrogen, decreased estrogen degradation and changes in the levels or activity of estrogen or androgen receptors. One of the primary causes of gynecomastia is hormonal imbalance, particularly an increase in estrogen levels relative to testosterone. Gynecomastia refers to the enlargement of breast tissue in males, which can be a source of embarrassment and self-consciousness for many individuals. Men are less likely to be diagnosed as having breast cancer at an early stage, but diagnosis at the preinvasive (in situ) stage has increased since the 1980s,18 perhaps owing to the heightened awareness of patients and clinicians. Surgery for gynecomastia may be recommended to reduce the size of the affected breast when the condition does not go away naturally within 2 years, interferes with daily activities, or causes embarrassment. Medical monitoring in this case is used only to observe how the breast tissue changes over time. Gynecomastia can be classified into several main types based on breast size, excess skin, and the characteristics of the breast tissue. The surgical technique used depends on the degree of the gynecomastia and the distribution and proportion of the different breast components (fat, parenchyma and looseness of the skin envelope). Testolactone is an aromatase inhibitor was tested in a small, uncontrolled trial of pubertal gynecomastia; results were positive.7,11 Overall, the use of aromatase inhibitors is supported by incomplete evidence and the potential benefits and adverse effects should be considered before commencing treatment. Aromatase Inhibitors–these powerful agents block estrogen synthesis and as such decrease the estrogen to androgen ratio. Because it rapidly reduces pain, it should be considered a first-line treatment for symptomatic cases of acute gynecomastia, or those that fail to resolve spontaneously. Gynecomastia (enlarged male breast tissue) most often happens due to an imbalance of testosterone and estrogen. Gynecomastia, a condition characterized by the enlargement of breast tissue in males, can be a source of physical and emotional discomfort. Hormones such as estrogen and testosterone play a significant role in maintaining the balance of breast tissue in both males and females. Gynecomastia, a condition characterized by the enlargement of breast tissue in males, is a topic that deserves understanding and attention. Such evaluation is unnecessary for boys at puberty, for typical asymptomatic senile changes, for enlargement consisting mostly of adipose tissue, for men taking drugs known to cause gynaecomastia, or for physical findings strongly suggesting breast cancer. Table 2 shows other genetic markers considered possible risk factors for male breast cancer. Use with extreme caution — crashed estrogen causes joint pain, mood issues, and libido death. When SERMs fail, Letrozole (Femara) nukes estrogen production completely. Suicidal AI means no estrogen rebound when you stop. Not all steroids carry equal gyno risk. A 33 year old man mentioned fatigue; headaches; painful, enlarged breasts; and impotence. Overall survival is shorter in men, possibly because they tend to be older and have more comorbid conditions. Men usually are offered adjuvant hormone therapy with tamoxifen 20 mg/day for five years, as several retrospective studies have shown improved survival.24 If the tumour has adverse features, adjuvant systemic therapy (chemotherapy or HER2 antibody trastuzumab, or both) should be offered. Complications include haematoma, seroma, infection, sensory changes, pain, breast asymmetry, skin redundancy, and scarring.22 23 The most common complication is a poor cosmetic outcome. As men age, testosterone levels may naturally decline while estrogen levels remain relatively stable. There are several factors and conditions that can contribute to hormonal imbalances and thus trigger gynecomastia. Read further to learn the gynecomastia symptoms, risk factors, secondary prevention, and various gynecomastia treatments. It usually presents as a soft, symmetrical swelling of the breast tissue, which can sometimes be tender or painful. However, TRT not always effective and can sometimes worsen gynecomastia if the excess testosterone converted into estrogen. Primary hypogonadism can lead to decreased T production, compensatory LH increase, Leydig cell stimulation, the inhibition of 17, 20-lyase and 17-hydroxylase activities, elevated aromatization of T to E2 and finally an increase in the ratio of E2 to T. Patients who develop re-feeding gynecomastia are therefore often described to be undergoing a ‘second puberty’. In the lead re-feeding gonadotropins are increased, leading to T secretion and E2 production, which mimics normal puberty. This hormonal imbalance causes the development of glandular breast tissue, leading to the enlargement of the breasts. In contrast, male breast cancer often feels like a hard or firm lump that may be painless. Hormone therapy or medications like selective estrogen receptor modulators (SERMs) may be used to reduce breast tissue growth. The excess estrogen then stimulates the growth of breast tissue, leading to gynecomastia. Maintaining a healthy weight and reducing body fat can help balance hormone levels and reduce breast tissue.
